Rapamycin prevents strong phosphorylation of p53 on serine 46 and attenuates activation of the p53 pathway in A549 lung cancer cells exposed to actinomycin D

Mechanisms of Ageing and Development

Volumn 139, Issue 1, 2014, Pages 11-21

  Krześniak, Małgorzata ^a   Zajkowicz, Artur ^a   Matuszczyk, Iwona ^a   Rusin, Marek ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Actinomycin D; P53; Phosphorylation; Rapamycin; Survivin

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; CAMPTOTHECIN; DACTINOMYCIN; MAMMALIAN TARGET OF RAPAMYCIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P53; RAPAMYCIN; RESVERATROL; SERINE; SURVIVIN; ANTINEOPLASTIC ANTIBIOTIC; MTOR PROTEIN, HUMAN; NUCLEAR PROTEIN; PML PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ANTIAGING ACTIVITY; ARTICLE; CELL CYCLE; CONTROLLED STUDY; DRUG ACTIVITY; GENE TARGETING; HUMAN; HUMAN CELL; LUNG CANCER; LUNG CANCER CELL LINE; MICROARRAY ANALYSIS; PML GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; AGING; DRUG EFFECTS; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

AGING; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DACTINOMYCIN; HUMANS; LUNG NEOPLASMS; NUCLEAR PROTEINS; PHOSPHORYLATION; SERINE; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84903388343     PISSN: 00476374     EISSN: 18726216     Source Type: Journal    
DOI: 10.1016/j.mad.2014.06.002     Document Type: Article

References (47)

1. Blagosklonny M.V. Rapamycin extends life- and health span because it slows aging. Aging (Albany, NY) 2013, 5:592-598.
2. Boehme K.A., Blattner C. Regulation of p53 - insights into a complex process. Crit. Rev. Biochem. Mol. Biol. 2009, 44:367-392.
3. Bulavin D.V., Saito S., Hollander M.C., Sakaguchi K., Anderson C.W., Appella E., Fornace A.J. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J. 1999, 18:6845-6854.
4. Campisi J. Aging, tumor suppression and cancer: high wire-act!. Mech. Ageing Dev. 2005, 126:51-58.
5. Deisenroth C., Zhang Y. Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway. Oncogene 2010, 29:4253-4260.
6. de Stanchina E., Querido E., Narita M., Davuluri R.V., Pandolfi P.P., Ferbeyre G., Lowe S.W. PML is a direct p53 target that modulates p53 effector functions. Mol. Cell 2004, 13:523-535.
7. D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S., Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G., Fanciulli M., Appella E., Soddu S. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell Biol. 2002, 4:11-19.
8. Dumont P., Leu J.I., Della Pietra A.C., George 3rd D.L., Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 2003, 33:357-365.
9. Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem. J. 2008, 415:333-344.
10. Feng Z., Levine A.J. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol. 2010, 20:427-434.
11. Ge H., Ni S., Wang X., Xu N., Liu Y., Wang X., Wang L., Song D., Song Y., Bai C. Dexamethasone reduces sensitivity to cisplatin by blunting p53-dependent cellular senescence in non-small cell lung cancer. PLoS ONE 2012, 7:e51821.
12. Gu B., Zhu W.G. Surf the post-translational modification network of p53 regulation. Int. J. Biol. Sci. 2012, 8:672-684.
13. Harrington L.S., Findlay G.M., Gray A., Tolkacheva T., Wigfield S., Rebholz H., Barnett J., Leslie N.R., Cheng S., Shepherd P.R., Gout I., Downes C.P., Lamb R.F. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 2004, 166:213-223.
14. Harrison D.E., Strong R., Sharp Z.D., Nelson J.F., Astle C.M., Flurkey K., Nadon N.L., Wilkinson J.E., Frenkel K., Carter C.S., Pahor M., Javors M.A., Fernandez E., Miller R.A. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460:392-395.
15. Hirai H., Sootome H., Nakatsuru Y., Miyama K., Taguchi S., Tsujioka K., Ueno Y., Hatch H., Majumder P.K., Pan B.S., Kotani H. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol. Cancer Ther. 2010, 9:1956-1967.
16. Imamura K., Ogura T., Kishimoto A., Kaminishi M., Esumi H. Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem. Biophys. Res. Commun. 2001, 287:562-567.
17. Jaks V., Jõers A., Kristjuhan A., Maimets T. p53 protein accumulation in addition to the transactivation activity is required for p53-dependent cell cycle arrest after treatment of cells with camptothecin. Oncogene 2001, 20:1212-1219.
18. Johnson S.C., Rabinovitch P.S., Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature 2013, 493:338-345.
19. Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J., Thompson C.B. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 2005, 18:283-293.
20. Kelly R.J., Lopez-Chavez A., Citrin D., Janik J.E., Morris J.C. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol. Cancer 2011, 10:35.
21. Kleiblova P., Shaltiel I.A., Benada J., Ševčík J., Pecháčková S., Pohlreich P., Voest E.E., Dundr P., Bartek J., Kleibl Z., Medema R.H., Macurek L. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint. J. Cell Biol. 2013, 201:511-521.
22. Kodama M., Otsubo C., Hirota T., Yokota J., Enari M., Taya Y. Requirement of ATM for rapid p53 phosphorylation at Ser46 without Ser/Thr-Gln sequences. Mol. Cell Biol. 2010, 30:1620-1633.
23. Kruse J.P., Gu W. Modes of p53 regulation. Cell 2009, 137:609-622.
24. Lee C.H., Inoki K., Karbowniczek M., Petroulakis E., Sonenberg N., Henske E.P., Guan K.L. Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. EMBO J. 2007, 26:4812-4823.
25. Liu L.F., Desai S.D., Li T.K., Mao Y., Sun M., Sim S.P. Mechanism of action of camptothecin. Ann. N. Y. Acad. Sci. 2000, 922:1-10.
26. Ma B.B., Lui V.W., Hui C.W., Lau C.P., Wong C.H., Hui E.P., Ng M.H., Tsao S.W., Li Y., Chan A.T. Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines. Invest. New Drugs 2013, 31:567-575.
27. Mirza A., McGuirk M., Hockenberry T.N., Wu Q., Ashar H., Black S., Wen S.F., Wang L., Kirschmeier P., Bishop W.R., Nielsen L.L., Pickett C.B., Liu S. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002, 21:2613-2622.
28. Möller A., Sirma H., Hofmann T.G., Rueffer S., Klimczak E., Dröge W., Will H., Schmitz M.L. PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res. 2003, 63:4310-4314.
29. Neff F., Flores-Dominguez D., Ryan D.P., Horsch M., Schröder S., Adler T., Afonso L.C., Aguilar-Pimentel J.A., Becker L., Garrett L., Hans W., Hettich M.M., Holtmeier R., Hölter S.M., Moreth K., Prehn C., Puk O., Rácz I., Rathkolb B., Rozman J., Naton B., Ordemann R., Adamski J., Beckers J., Bekeredjian R., Busch D.H., Ehninger G., Graw J., Höfler H., Klingenspor M., Klopstock T., Ollert M., Stypmann J., Wolf E., Wurst W., Zimmer A., Fuchs H., Gailus-Durner V., Hrabe de Angelis M., Ehninger D. Rapamycin extends murine lifespan but has limited effects on aging. J. Clin. Invest. 2013, 123:3272-3291.
30. Nogi Y., Kanno T., Nakano T., Fujita Y., Tabata C., Fukuoka K., Gotoh A., Nishizaki T. AMP converted from intracellularly transported adenosine upregulates p53 expression to induce malignant pleural mesothelioma cell apoptosis. Cell. Physiol. Biochem. 2012, 30:61-74.
31. Oda K., Arakawa H., Tanaka T., Matsuda K., Tanikawa C., Mori T., Nishimori H., Tamai K., Tokino T., Nakamura Y., Taya Y. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000, 102:849-862.
32. Okoshi R., Ozaki T., Yamamoto H., Ando K., Koida N., Ono S., Koda T., Kamijo T., Nakagawara A., Kizaki H. Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J. Biol. Chem. 2008, 283:3979-3987.
33. Orsted D.D., Bojesen S.E., Tybjaerg-Hansen A., Nordestgaard B.G. Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. J. Exp. Med. 2007, 204:1295-1301.
34. Ruark E., Snape K., Humburg P., Loveday C., Bajrami I., Brough R., Rodrigues D.N., Renwick A., Seal S., Ramsay E., Duarte Sdel V., Rivas M.A., Warren-Perry M., Zachariou A., Campion-Flora A., Hanks S., Murray A., Ansari Pour N., Douglas J., Gregory L., Rimmer A., Walker N.M., Yang T.P., Adlard J.W., Barwell J., Berg J., Brady A.F., Brewer C., Brice G., Chapman C., Cook J., Davidson R., Donaldson A., Douglas F., Eccles D., Evans D.G., Greenhalgh L., Henderson A., Izatt L., Kumar A., Lalloo F., Miedzybrodzka Z., Morrison P.J., Paterson J., Porteous M., Rogers M.T., Shanley S., Walker L., Gore M., Houlston R., Brown M.A., Caufield M.J., Deloukas P., McCarthy M.I., Todd J.A., Breast and Ovarian Cancer Susceptibility Collaboration, Wellcome Trust Case Control Consortium, Turnbull C., Reis-Filho J.S., Ashworth A., Antoniou A.C., Lord C.J., Donnelly P., Rahman N. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature 2013, 493:406-410.
35. Rusin M., Zajkowicz A., Butkiewicz D. Resveratrol induces senescence-like growth inhibition of U-2 OS cells associated with the instability of telomeric DNA and upregulation of BRCA1. Mech. Ageing Dev. 2009, 130:528-537.
36. Sahin E., DePinho R.A. Axis of ageing: telomeres, p53 and mitochondria. Nat. Rev. Mol. Cell Biol. 2012, 13:397-404.
37. Shackelford D.B., Shaw R.J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 2009, 9:563-575.
38. Shi Y., Yan H., Frost P., Gera J., Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol. Cancer Ther. 2005, 4:1533-1540.
39. Smeenk L., van Heeringen S.J., Koeppel M., Gilbert B., Janssen-Megens E., Stunnenberg H.G., Lohrum M. Role of p53 serine 46 in p53 target gene regulation. PLoS ONE 2011, 6:e17574.
40. Taira N., Nihira K., Yamaguchi T., Miki Y., Yoshida K. DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Mol. Cell 2007, 25:725-738.
41. Taylor W.R., Stark G.R. Regulation of the G2/M transition by p53. Oncogene 2001, 20:1803-1815.
42. Yap T.A., Yan L., Patnaik A., Fearen I., Olmos D., Papadopoulos K., Baird R.D., Delgado L., Taylor A., Lupinacci L., Riisnaes R., Pope L.L., Heaton S.P., Thomas G., Garrett M.D., Sullivan D.M., de Bono J.S., Tolcher A.W. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J. Clin. Oncol. 2011, 29:4688-4695.
43. Yoshida K., Liu H., Miki Y. Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor suppressor in the apoptotic response to DNA damage. J. Biol. Chem. 2006, 281:5734-5740.
44. Zajkowicz A., Rusin M. The activation of the p53 pathway by the AMP mimetic AICAR is reduced by inhibitors of the ATM or mTOR kinases. Mech. Ageing Dev. 2011, 132:543-551.
45. Zajkowicz A., Krześniak M., Matuszczyk I., Głowala-Kosińska M., Butkiewicz D., Rusin M. Nutlin-3a, an MDM2 antagonist and p53 activator, helps to preserve the replicative potential of cancer cells treated with a genotoxic dose of resveratrol. Mol. Biol. Rep. 2013, 40:5013-5026.
46. Zhou J., Oliveira P., Li X., Chen Z., Bepler G. Modulation of the ribonucleotide reductase-antimetabolite drug interaction in cancer cell lines. J. Nucleic Acids 2010, 2010:597098.
47. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12:21-35.